This company is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Humanigen Croissance future
Future contrôle des critères 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Humanigen.
Informations clés
n/a
Taux de croissance des bénéfices
n/a
Taux de croissance du BPA
Biotechs croissance des bénéfices | 28.5% |
Taux de croissance des recettes | n/a |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | None |
Dernière mise à jour | n/a |
Mises à jour récentes de la croissance future
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Humanigen n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.
Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.
Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
3/31/2023 | 2 | -54 | -64 | -64 | N/A |
12/31/2022 | 3 | -71 | -77 | -77 | N/A |
9/30/2022 | 3 | -109 | -94 | -94 | N/A |
6/30/2022 | 4 | -152 | -125 | -125 | N/A |
3/31/2022 | 4 | -192 | -168 | -168 | N/A |
12/31/2021 | 4 | -237 | -184 | -184 | N/A |
9/30/2021 | 3 | -235 | -175 | -175 | N/A |
6/30/2021 | 2 | -199 | -151 | -151 | N/A |
3/31/2021 | 1 | -153 | -105 | -105 | N/A |
12/31/2020 | 0 | -90 | -70 | -70 | N/A |
9/30/2020 | N/A | -59 | -47 | -47 | N/A |
6/30/2020 | N/A | -31 | -24 | -24 | N/A |
3/31/2020 | N/A | -10 | -4 | -4 | N/A |
12/31/2019 | N/A | -10 | -4 | -4 | N/A |
9/30/2019 | N/A | -10 | -5 | -5 | N/A |
6/30/2019 | N/A | -10 | -5 | -5 | N/A |
3/31/2019 | N/A | -9 | -5 | -5 | N/A |
12/31/2018 | N/A | -12 | -6 | -6 | N/A |
9/30/2018 | N/A | -13 | -7 | -7 | N/A |
6/30/2018 | N/A | -18 | -10 | -10 | N/A |
3/31/2018 | N/A | -22 | -12 | -12 | N/A |
12/31/2017 | N/A | -22 | -14 | -14 | N/A |
9/30/2017 | N/A | -24 | -15 | -15 | N/A |
6/30/2017 | N/A | -21 | -20 | -20 | N/A |
3/31/2017 | N/A | -27 | -23 | -23 | N/A |
12/31/2016 | N/A | -27 | N/A | -21 | N/A |
9/30/2016 | N/A | -35 | N/A | -26 | N/A |
6/30/2016 | N/A | -37 | N/A | -23 | N/A |
3/31/2016 | N/A | -31 | N/A | -22 | N/A |
12/31/2015 | N/A | -35 | N/A | -29 | N/A |
9/30/2015 | N/A | -32 | N/A | -28 | N/A |
6/30/2015 | N/A | -33 | N/A | -30 | N/A |
3/31/2015 | N/A | -37 | N/A | -34 | N/A |
12/31/2014 | N/A | -38 | N/A | -36 | N/A |
9/30/2014 | 0 | -39 | N/A | -39 | N/A |
6/30/2014 | 0 | -42 | N/A | -39 | N/A |
3/31/2014 | 0 | -44 | N/A | -42 | N/A |
12/31/2013 | 0 | -42 | N/A | -39 | N/A |
9/30/2013 | 0 | -43 | N/A | -37 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if HGEN.Q's forecast earnings growth is above the savings rate (2.4%).
Bénéfices vs marché: Insufficient data to determine if HGEN.Q's earnings are forecast to grow faster than the US market
Croissance élevée des bénéfices: Insufficient data to determine if HGEN.Q's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: Insufficient data to determine if HGEN.Q's revenue is forecast to grow faster than the US market.
Croissance élevée des revenus: Insufficient data to determine if HGEN.Q's revenue is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if HGEN.Q's Return on Equity is forecast to be high in 3 years time